Literature DB >> 11322833

Proteases in invasion: matrix metalloproteinases.

W G Stetler-Stevenson1, A E Yu.   

Abstract

The role of proteases in general, and the matrix metalloproteinases in particular, in tumor invasion and metastasis is well established. However, the classic view that these enzymes simply provide a mechanism for the breakdown of connective tissue barriers has been challenged. This overview summarizes recent evidence to support the changing view of the role of matrix metalloproteinases in cancer progression. First we briefly review the central role of cell invasion in cancer progression and also the matrix metalloproteinase family members. We then focus on the emerging roles for these enzymes in cancer progression, including the role of matrix metalloproteinases in cell proliferation and release of growth factors, cell migration and in modification of the extracellular matrix to reveal cryptic sites that alter cell behaviour. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322833     DOI: 10.1006/scbi.2000.0365

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  101 in total

1.  Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.

Authors:  Dimitra Bourboulia; Sandra Jensen-Taubman; Matthew R Rittler; Hui Ying Han; Tania Chatterjee; Beiyang Wei; William G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2011-09-18       Impact factor: 4.307

2.  Endoglin suppresses human prostate cancer metastasis.

Authors:  Minalini Lakshman; Xiaoke Huang; Vijayalakshmi Ananthanarayanan; Borko Jovanovic; Yueqin Liu; Clarissa S Craft; Diana Romero; Calvin P H Vary; Raymond C Bergan
Journal:  Clin Exp Metastasis       Date:  2010-10-28       Impact factor: 5.150

3.  Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.

Authors:  Michael I Dorrell; Edith Aguilar; Lea Scheppke; Faith H Barnett; Martin Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

4.  Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration.

Authors:  Elisabeth L Bair; Man Ling Chen; Kathy McDaniel; Kiyotoshi Sekiguchi; Anne E Cress; Raymond B Nagle; George Timothy Bowden
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 5.  Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.

Authors:  Dimitra Bourboulia; William G Stetler-Stevenson
Journal:  Semin Cancer Biol       Date:  2010-05-12       Impact factor: 15.707

6.  Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid.

Authors:  Zornitsa I Zlatarova; Ekaterina B Softova; Klara G Dokova; Elisabeth M Messmer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-01       Impact factor: 3.117

Review 7.  MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer.

Authors:  Anjum Sohail; Qing Sun; Huiren Zhao; M Margarida Bernardo; Jin-Ah Cho; Rafael Fridman
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

Review 8.  Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.

Authors:  Ajay Kumar Chaudhary; Mamta Singh; Alok C Bharti; Kamlesh Asotra; Shanthy Sundaram; Ravi Mehrotra
Journal:  J Biomed Sci       Date:  2010-02-15       Impact factor: 8.410

9.  P-cadherin counteracts myosin II-B function: implications in melanoma progression.

Authors:  Koen Jacobs; Mireille Van Gele; Ramses Forsyth; Lieve Brochez; Barbara Vanhoecke; Olivier De Wever; Marc Bracke
Journal:  Mol Cancer       Date:  2010-09-22       Impact factor: 27.401

10.  Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion.

Authors:  Valentina Masola; Claudio Maran; Evelyne Tassone; Angelica Zin; Angelo Rosolen; Maurizio Onisto
Journal:  BMC Cancer       Date:  2009-08-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.